Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.

Biological psychiatry - 1 May 2009

Perlis Roy H, Fijal Bonnie, Adams David H, Sutton Virginia K, Trivedi Madhukar H, Houston John P

Abstract excerpt

BACKGROUND: The study objective was to evaluate variations in genes implicated in antidepressant mechanism of action for association with response to duloxetine treatment in major depressive disorder (MDD). METHODS: We assessed response over 6 weeks in 250 duloxetine-treated Caucasian patients in a randomized, double-blind study of patients with MDD. Single nucleotide polymorphisms (SNPs) were genotyped in 19...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catechol O-Methyltransferase
Share to Depressive Disorder, Major

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Genome-Wide Association Study

Share to Receptor, Serotonin, 5-HT2A

Share to Selective Serotonin Reuptake Inhibitors

Share to Thiophenes

Share to Treatment Outcome

Source

Identifiers

PMID: 19095219
DOI: 10.1016/j.biopsych.2008.10.002

Genes

COMT
IDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.PMID 19095219Read ↗

Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.Semantic proximity Read ↗

Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).Semantic proximity Read ↗

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.Semantic proximity Read ↗

The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.Semantic proximity Read ↗

Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.Semantic proximity Read ↗

Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.Semantic proximity Read ↗

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.Semantic proximity Read ↗

Depression and the role of genes involved in dopamine metabolism and signalling.Semantic proximity Read ↗

Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Genome-wide association studies of placebo and duloxetine response in major depressive disorder.Semantic proximity Read ↗

The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.Semantic proximity Read ↗

DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.